Multivalent EBV VLP Vaccine Merging Humoral and Cellular Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current EBV vaccines have shown low efficacy due to their inability to elicit robust antibody and T cell responses, as they primarily target either humoral or T cell-mediated immunity, and none have achieved sterile immunity or effectively prevented EBV infection.
Innovation Solution
Development of virus-like particles (VLPs) comprising two or more EBV envelope glycoproteins and one or more T cell antigens, such as gp350, gB, gp42, gH, gL, and antigens like EBNA1 and LMP2, which are designed to stimulate both humoral and cellular immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-antigen vaccines are used to target either humoral or T cell-mediated immunity, then the vaccine structure remains simple, but the immune response efficacy is limited
Solution Approach 1:
The patent combines multiple EBV antigens (gp350, gB, gp42, gH, gL envelope glycoproteins and EBNA1, EBNA2, EBNA3a, EBNA3b, EBNA3c, LMP1, LMP2 T cell antigens) into a single virus-like particle to simultaneously elicit both humoral and T cell-mediated immune responses, resolving the contradiction between vaccine simplicity and immune efficacy
Solution Approach 2:
The VLP platform serves multiple functions: it presents multiple envelope glycoproteins for neutralizing antibody production and multiple T cell antigens for cellular immunity, making a single vaccine capable of addressing both arms of the immune system against EBV
2Reliability
If multiple EBV antigens are incorporated into VLPs to stimulate both humoral and cellular immunity, then immune response robustness is enhanced, but the vaccine development complexity increases
Solution Approach 1:
The patent nests multiple EBV antigens within the VLP structure, where envelope glycoproteins are displayed on the particle surface and T cell antigens are incorporated internally or on surface, allowing complex multivalent composition while maintaining a unified vaccine platform
3Reliability
If previous candidate vaccines targeted only one arm of the immune system, then the vaccine design was simpler, but the overall protection against EBV was insufficient
Solution Approach 1:
The vaccine merges humoral immunity targeting (via envelope glycoproteins gp350, gB, gp42, gH, gL) and T cell immunity targeting (via T cell antigens EBNA1, EBNA2, EBNA3a, EBNA3b, EBNA3c, LMP1, LMP2) into a single formulation, achieving comprehensive EBV protection by activating both immune arms simultaneously
Data Source
AI summary
Disclosed are vaccine compositions comprising a VLP comprising two or more EBV envelope glycoproteins and one or more T cell antigens and methods of preventing or treating EBV infections using the vaccine compositions. Also disclosed is an expression system or a single expression vector for co-expressing two or more EBV envelope glycoproteins simultaneously to generate a VLP vaccine. The expression system may include a single vector inserted with two or more nucleic acid sequences that encode two or more EBV envelope glycoproteins linked by one or more linking sequences such that the EBV envelope glycoproteins are co-expressed simultaneously.